Abstract 158P
Background
C-reactive protein/albumin (CRP/Alb) ratio has been identified to be associated with prognosis in pancreatic cancer. However, the role of it in biliary tract cancers has not been examined. The aim of this study is to assess the role of CRP/Alb in curatively resected extrahepatic bile duct cancers (EBDC).
Methods
We retrospectively analyzed 235 patients who underwent curative resection because of EBDC in Seoul National University Bundang Hospital between March 2005 and February 2018. The laboratory data including CRP and albumin levels were obtained by blood tests prior to surgery. The correlations among the preoperative CRP/Alb ratio, clinicopathological factors, and patient outcomes were investigated.
Results
Men were 143 (60.8%) and mean age was 68 years (range 41–85 years). EBDC perihilar bile duct cancer (n = 61) and distal bile duct cancer (n = 174). Median follow-up was 22 months and median recurrence free survival 17 months, respectively. The optimal prognostic cut-off point of the CRP/Alb ratio for tumor recurrence was 0.18. Multivariate logistic regression analysis for overall survival showed age older than 65 (HR 1.937; 95% CI 1.275–2.944; p = 0.002), advanced staging (Reference stage I, stage II - HR 1.963; 95% CI 1.261–3.056; p = 0.004, stage III - HR 2.158; 95% CI 1.155–4.031; p = 0.016), Increased CA 19-9 (HR 1.735; 95% CI 1.069–2.816; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.638; 95% CI 1.102–2.434; p = 0.015). Multivariate logistic regression analysis for recurrence free survival showed advanced staging (Reference stage I, stage II - HR 1.750; 95% CI 1.127–2.717; p = 0.013), venous invasion (HR 1.742; 95% CI 1.097–2.767; p = 0.019), perineural invasion (HR 2.427; 95% CI 1.114–5.287; p = 0.026), and CRP/Alb ratio ³ 0.18 (HR 1.702; 95% CI 1.144–2.531; p = 0.009).
Conclusions
Preoperative CRP/Alb ratio is significantly associated with recurrence and overall in patients with resected EBDC. Further studies are necessary to assess the role of preoperative CRP/Alb ratio in EBDC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Bundang Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract